TT125-802
Solid tumors and hematological malignancies (for prevention of resistance)
Phase 1Active
Key Facts
Indication
Solid tumors and hematological malignancies (for prevention of resistance)
Phase
Phase 1
Status
Active
Company
About Tolremo Therapeutics
Tolremo Therapeutics is a private, clinical-stage biotech tackling a fundamental challenge in oncology: non-genetic, adaptive resistance to targeted cancer therapies. The company's core discovery is the role of CBP/p300 as an epigenetic master regulator of transcriptional escape pathways. Its lead asset, TT125-802, is an oral, selective CBP/p300 bromodomain inhibitor currently in Phase 1 trials, demonstrating initial monotherapy activity and planned for combination regimens to prevent resistance. Tolremo's strategy aims to transform targeted therapies into durable treatments across solid and hematological tumors.
View full company profile